Report

Global ENT Disorder Treatment Market Size study & Forecast, by Drug Type (Antibiotics Drugs, Anti Inflammatory Drugs, Others), by Organ (Throat, Ear, Nose), by End User (Hospital & clinics, Homecare Settings, Others) & Regional Analysis, 2022-2029

  • Publish Date: Jan,2023
  • Report ID: 3-2-1361
  • Page : 200
  • Report Type : PDF (Email)
Global ENT Disorder Treatment Market is valued approximately USD 2.4 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2022-2029. ENT Disorder refers to infections associated with ear, nose and throat that caused by bacteria and viruses. Ear infection can cause hearing loss, earache, discharge from ear. Whereas nose & throat disorders can cause sore throat, runny nose, snoring, sleep apnea, and breathing difficulty among others. Moreover, there are different treatment options available for ENT disorders including antibiotics, anti- inflammatory drugs etc. The increasing number of geriatric individuals and growing prevalence of infectious diseases as well as strategic initiatives from leading market players are key factors accelerating the market growth.

According to the World Health Organization (WHO) - in 2019, globally approximately 2.6 million individuals lost their lives due to lower respiratory infections. Moreover, as per Australian Institute of Health and Welfare estimates - in financial year 2020-21, Australia witnessed more than 324,000 hospitalizations for infectious diseases, out of which around 94% were for non-notifiable diseases. Also, growing pollution levels worldwide and rising healthcare spending in developing regions would create lucrative growth prospectus for the market over the forecast period. However, the high cost of medical devices impedes the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global ENT Disorder Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as presence of leading market players and growing prevalence of infectious diseases in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric population as well as increasing incidences of respiratory disorders in the region.

Major market players included in this report are:

Sanofi

Novartis

GSK

Pfizer

Vitaris

Sun Pharma

AstraZeneca

Cipla

AurbindoPharma

Teva Pharmaceuticals

Recent Developments in the Market:

In August 2020, Hyderabad, India based Dr Reddy's Laboratories launched a generic version of Ciprodex in the United States. This new drug is intended for treatment of ear infections.
In October 2021, Cipla Pharmaceuticals launched an anti-viral nasal spray named Naselin. This new spray contains 'povidone Iodine' that protects against coronavirus and respiratory tract infections.
Global ENT Disorder Treatment Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Drug Type, Organ, End User, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Type

Antibiotics Drugs

Anti-Inflammatory Drugs

Others

By Organ

Throat

Ear

Nose

By End User

Hospital and clinics

Homecare Settings

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World